Is Glenmark Life Sciences another Divi's in the making?
Glenmark Life Sciences' IPO timing is opportune, but it needs to strike deep relationships with global innovators and attain market leadership in key products
July 22, 2021 / 09:49 AM IST
Glenmark Pharmaceuticals has chosen an opportune time to launch the initial public offering (IPO) of its subsidiary Glenmark Life Sciences. Primary markets are red hot and the company has encouraging numbers to back its issue. Revenues are up 22.6 percent last fiscal and the company’s profitability is notably better than many of its local peers.
Still, prospective investors in its IPO will be keen to know its future potential. Can it replicate the success of Divi's Laboratories, a large active pharmaceutical ingredients (API) manufacturer based out of...